| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Analysts' ratings for Ventas (NYSE:VTR) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 2 | 2 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 1 | 0 | 0 |
| 2M Ago | 0 | 1 | 1 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts have set 12-month price targets for Ventas, revealing an average target of $74.25, a high estimate of $78.00, and a low estimate of $72.00. This current average has increased by 4.21% from the previous average price target of $71.25.
A comprehensive examination of how financial experts perceive Ventas is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Jonathan Hughes | Raymond James | Raises | Outperform | $78.00 | $74.00 |
| Richard Hill | Morgan Stanley | Raises | Equal-Weight | $75.00 | $70.00 |
| Nicholas Yulico | Scotiabank | Raises | Sector Perform | $72.00 | $71.00 |
| Michael Mueller | JP Morgan | Raises | Overweight | $72.00 | $70.00 |
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Ventas's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Ventas analyst ratings.
Ventas owns a diversified healthcare portfolio of almost 1,400 in-place properties spread across the senior housing, medical office, hospital, life science, and skilled nursing/post-acute care. The portfolio includes almost 100 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to the United States. The firm also owns mortgages and other loans, contributing about 1% of net operating income.
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Ventas's revenue growth over a period of 3M has been noteworthy. As of 30 June, 2025, the company achieved a revenue growth rate of approximately 18.31%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Real Estate sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Ventas's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 4.8%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Ventas's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 0.59%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Ventas's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.26% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Ventas's debt-to-equity ratio is below the industry average. With a ratio of 1.15, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: VTR
